About Translational Neuroscience
Translational Neuroscience research helps to provide R & D continuum from discovery to clinical phases by gathering multidisciplinary expertise, state-of-the-art technology platforms and innovative methodologies.
Neurodegenerative diseases market covers a large and diverse pipeline of almost 1 500 products. However, not a single therapeutic approach exists to prevent or even slow down degeneration in AD, PD, HD and MS.
Translational Neuroscience research is a mandatory step in drug development to ensure that the next generation of innovative strategies will be made available for the benefit of patients and society.
About our event “Translational Neuroscience Day”
For the third edition, Dhune and NeurATRIS decided to join their expertise to offer an event that will highlight innovative translational research for neurodegenerative diseases with a market focus. Thus, academia-industry relationships will be developed not only from the science and technology point of view but also through training / education required to constantly remain at the forefront of innovation.
This new edition will gather experts in neurodegenerative diseases and foster interactions between researchers, clinicians, biotech and pharmaceutical companies.
The programme in a nutshell
9:00 am – 10:30 am
Translational Research Infrastructures
9:00 – 9:20 am: DHUNE – Olivier Blin, Pharmacology Professor, DHUNE director
9:20 – 9:40 am: NEURATRIS – Philippe Hantraye, Director of MIRCen (CEA) and NeurATRIS
9:40 – 10:00 am: Stakes in rare diseases – Philippe Berta, Professor of Universities and Deputy
10:00 – 10:30 am: Brain diseases: Advances, challenges and obstacles – Catherine Lubetzki, Neurology Professor, Head of neurologic diseases department at Pitié-Salpêtrière Hospital, Paris
10:30 am – 11:00 am
COFFEE BREAK (within BioFIT Exhibition hall)
11:00 am – 12:30 pm
Round table I
Role of public and industry actors in neuroscience translational research – What mechanisms and resources to support translation up to phase 2?
Moderator: Toni Andreu – CSO EATRIS-ERIC
Angel Cedazo-Miguez, Head of neurodegeneration research – Rare and Neurologic Diseases Research TA – Sanofi
Aline Jourdain, Deep Tech Innovation Manager – BPI
Michel Khrestchatisky, Co-founder of Vect-Horus – Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS
Emmanuel Le Bouder, Innovation project manager – Eurobiomed
Catherine Lubetzki, Neurology Professor, Head of neurologic diseases department at Pitié-Salpêtrière Hospital
Bruno Marroni, Head of Protisvalor
12:30 pm – 2:00 pm
NETWORKING LUNCH (within BioFIT exhibition hall)
2:00 pm – 3:30 pm
Round table II
Stakes of training in translational neuroscience research – State-of-the-art and needs of academia and industry
Moderator: François Féron – NeuroSchool Director
Introduction of a market study on Translational neuroscience training by Vincent Gleize, Senior innovation consultant – Erdyn
Olivier Blin, Pharmacology Professor, DHUNE director
Marc Dhenain, Head of DIU « translational research and therapeutic innovation in nervous system diseases » (NeurATRIS and MIRCen)
Corinne Grenier, Professor at KEDGE Business School – Director of Health Management research center
Rosan Vegter, Scientific and Education manager, EATRIS-ERIC
3:30 pm – 4:00 pm
COFFEE BREAK (within BioFIT Exhibition hall)
4:00 pm – 5:40 pm
Advanced translational projects
4:00 – 4:20 pm: Lionel Lamothe, CEO Exostim – SHS: ExoStim, cognitive stimulation 3.0
4:20 – 4:40 pm: Mathieu Charveriat, CSO Theranexus – NeuroLead, an public-private collaboration in neurosciences
4:40 – 5:00 pm: Michel Khrestchatisky, Co-founder of Vect-Horus – Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS – From blood to brain to clinical development
5:00 – 5:20 pm: Sylvie Claeysen, Project leader at Institute of Functional Genomics at Montpellier University – Donecopride, a multi-target-directed ligand with potential interest against Alzheimer’s disease
5:20 – 5:40 pm: Philippe Verwaerde, CEO at AlzProtect – AZP2006 a first in class new neuroprotective compound for the treatment of Alzheimer’s disease and related neurodegenerative diseases
DHUNE is an initiative of French government which aims to federate both public and private stakeholders from the south French region involved in the field of neurodegenerative diseases and aging. The objective of DHUNE is to accelerate the research and the innovation using a large and integrated medico-socio-economic network with more than one hundred twenty industrial and academic partners.
NeurATRIS is a French research infrastructure conceived to accelerate the translation of discoveries in basic research into medical innovations in order to develop innovative approaches for the diagnosis and treatment for neurodegenerative diseases. NeurATRIS also offers an access to a powerful range of expertise and state-of-the-art platforms covering the entire value chain of neuroscience translational research.
GOOD TO KNOW:
Members of NEURATRIS or DHUNE network: Registration for Translational Neuroscience is free but mandatory. If you want to attend BioFIT on December 11th, you benefit from a special rate.
Not part of NEURATRIS or DHUNE network: You must be registered for BioFIT to attend Translational Neuroscience, you benefit from a special rate.
If you are already registered for BioFIT: The access to Translational Neuroscience is free.